Revenue
2017
2018
2019
2020
2021
2022
2023
2024
2025
Bicycle Therapeutics PLC (BCYC)
Price$4.30Cached quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72.6M | $35.3M | $27.0M | $14.5M | $11.7M | $10.4M | $13.8M | $7.1M | $2.1M |
| Research & development | $240.3M | $173.0M | $156.5M | $81.6M | $44.9M | $33.1M | $25.5M | $20.8M | $11.9M |
| Operating expenses | $319.7M | $245.1M | $216.9M | $131.1M | $77.3M | $62.4M | $40.1M | $28.9M | $18.3M |
| Operating income | −$247.1M | −$209.9M | −$189.9M | −$116.7M | −$65.6M | −$52.0M | −$26.3M | −$21.7M | −$16.2M |
| Operating margin | −340.38% | −594.96% | −704.13% | −806.56% | −560.98% | −500.10% | −190.56% | −304.74% | −787.04% |
| EBITDA | −$240.6M | −$202.7M | −$183.4M | −$113.0M | −$64.2M | −$50.7M | −$25.3M | −$21.0M | −$15.9M |
| EBITDA margin | −331.53% | −574.62% | −679.86% | −781.06% | −548.94% | −487.81% | −183.60% | −294.76% | −770.92% |
| Net income | −$219.0M | −$169.0M | −$180.7M | −$112.7M | −$66.8M | −$51.0M | −$30.6M | −$21.8M | −$16.3M |
| Net profit margin | −301.66% | −479.18% | −669.72% | −779.35% | −571.25% | −490.95% | −221.78% | −306.14% | −789.27% |
| Basic EPSper basic share | -$3.16 | -$2.90 | -$5.08 | -$3.80 | -$2.67 | -$2.66 | -$2.77 | -$49.78 | -$48.81 |
| Diluted EPSper diluted share | -$3.16 | -$2.90 | -$5.08 | -$3.80 | -$2.67 | -$2.66 | -$2.77 | -$49.78 | -$48.81 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
BAKER BROS. ADVISORS LP | 10.89M |
FCPM III SERVICES B.V. | 3.47M |
ARMISTICE CAPITAL, LLC | 3.4M |
Long Focus Capital Management, LLC | 3.31M |
ACADIAN ASSET MANAGEMENT LLC | 1.97M |
RENAISSANCE TECHNOLOGIES LLC | 1.53M |
GSK plc | 1.53M |
PRICE T ROWE ASSOCIATES INC /MD/ | 902.15K |
MARSHALL WACE, LLP | 797.94K |
Qube Research & Technologies Ltd | 775.57K |
MORGAN STANLEY | 667.27K |
SCHRODER INVESTMENT MANAGEMENT GROUP | 615.83K |
Lee Kevin | 611.31K |
CITADEL ADVISORS LLC | 554.23K |
MILLENNIUM MANAGEMENT LLC | 553.97K |
Peapod Lane Capital LLC | 537.98K |
DIADEMA PARTNERS LP | 462.72K |
TWO SIGMA INVESTMENTS, LP | 434.58K |
JANE STREET GROUP, LLC | 392.16K |
FLAX POND CAPITAL, LLC | 376.22K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 6, 2026Form 4 · 10b5-1 | Perry Jennifer ScottChief Operating Officer | SellOrdinary Shares | 333 | $5.04 | $1.7K | 92.5K |
| Apr 6, 2026Form 4 · 10b5-1 | Perry Jennifer ScottChief Operating Officer | SellOrdinary Shares | 37 | $5.05 | $186.85 | 92.8K |
| Apr 6, 2026Form 4 | Hannay Michael Charles FergusonCHIEF PROD & SUPPLY CHAIN OFF | SellOrdinary Shares | 251 | $5.05 | $1.3K | 96.1K |
| Apr 6, 2026Form 4 | Thompson Travis AlvinChief Financial Officer | SellOrdinary Shares | 102 | $5.05 | $515.10 | 65.4K |
| Apr 6, 2026Form 4 | Lee KevinCHIEF EXECUTIVE OFFICER | SellOrdinary Shares | 1.7K | $5.05 | $8.7K | 611.3K |